<DOC>
	<DOCNO>NCT02672644</DOCNO>
	<brief_summary>Study design characterize subject treat investigator report outcomes early post-treatment period , follow bilateral correction nasolabial fold use Emervel Classic Emervel Deep . 1. evaluate subject-reported return social engagement , initial treatment ( Baseline/Day 1 visit ) . 2. evaluate change Global Aesthetic Improvement Scale ( GAIS ) day 30- subject/investigator report 3. evaluate subject satisfaction treatment outcome baseline , day 14 day 30 . 4. evaluate change Wrinkle Severity Rating Scale ( WSRS ) baseline post-treatment follow-up time point day 14 Day 30 - investigator report 5. evaluate adverse event course study</brief_summary>
	<brief_title>Non-comparative Evaluation Facial Expressions Following Lower Face Correction Using Emervel Classic Emervel Deep</brief_title>
	<detailed_description />
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>Key 1 . Male female subject , 35 60 year age 2 . Bilateral NLFs : severe ( WSRS = 4/4 ) moderate ( WSRS = 3/3 ) , assess treat investigator 3 . Subjects childbearing potential agree use medically accept method contraception study 30 day follow study completion . Childbearing potential define surgically sterile ( e.g. , hysterectomy , bilateral salpingooophorectomy , tubal ligation ) postmenopausal ( absence menstruation least 1 year prior Day 1 ) . If surgically sterile postmenopausal , subject agrees use acceptable form contraception . Acceptable method contraception define follow : 1. use oral/systemic contraceptive least 3 month prior start study ; 2. use intrauterine device ; 3. use double barrier ( e.g. , condom diaphragm spermicidal foam/gel , condom diaphragm ) ; 4. use contraceptive implant injectables least 28 day prior start study ; 5. partner vasectomy least 3 month prior study start ; 6. strict abstinence . Females child bear potential must negative urine pregnancy test ( UPT ) Day 1 Day 14 touchup perform . Key 1 . Subject present severity wrinkle fold require treatment , e.g . laser treatment , chemical peeling , achieve optimal correction 2 . Previous facial surgery , include aesthetic facial surgical therapy , liposuction tattoo , treatment area 3 . Previous tissue augment therapy contour permanent fillertype injectable product 4 . Previous tissue augment therapy nonpermanent filler fatinjection facial area treat , within twelve ( 12 ) month treatment 5 . Previous tissue revitalisation treatment neurotoxin zygomatic arch , within six ( 6 ) month treatment 6 . Previous tissue revitalisation treatment laser light , mesotherapy , chemical peel dermabrasion zygomatic arch within six ( 6 ) month treatment 7 . Subject present severe midface volume loss 8 . Subject beard facial hair , investigator 's opinion , would interfere study injection and/or study assessment 9 . Woman plan become pregnant study 10 . Woman pregnant breast feed 11 . Known/previous allergy hypersensitivity injectable hyaluronic acid ( HA ) gel 12 . Known/previous allergy hypersensitivity local anaesthetic , e.g . lidocaine amidetype anaesthetic 13 . Known/previous allergy hypersensitivity grampositive bacterial protein 14 . History severe multiple allergy manifest anaphylaxis 15 . History bleed disorder treatment anticoagulant inhibitor platelet aggregation within two ( 2 ) week treatment 16 . Treatment chemotherapy , immunosuppressive agent , immunomodulatory therapy ( e.g . monoclonal antibody ) , systemic topical ( facial ) corticosteroid ( inhaled corticoid allow ) within three ( 3 ) month study treatment 17 . Any medical condition treatment , opinion treat investigator , would make subject unsuitable inclusion 18 . Study site personnel , close relative study site personnel ( e.g . parent , child , sibling , spouse ) , employee , close relative employee Sponsor company 19 . Participation clinical study within thirty ( 30 ) day treatment</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>